/PRNewswire/ -- In a groundbreaking step toward advancing gene therapy manufacturing, Kyfora Bio launched

/PRNewswire/ -- 为了推进基因治疗制造，Kyfora Bio开创性地启动了

KyFect™ - AAV

KyFect™ - AAV

, a next-generation transfection reagent designed specifically for high-yield, scalable viral titers.

，一种专为高产量、可扩展病毒滴度设计的下一代转染试剂。

As recombinant adeno-associated virus (AAV)-based therapies lead the way in gene therapy innovation, the industry faces persistent challenges related to scalability and cost. With six FDA-approved AAV therapies already on the market and more in late-stage clinical trials, the need to optimize upstream manufacturing has never been greater..

随着基于重组腺相关病毒 (AAV) 的疗法在基因治疗创新中处于领先地位，行业面临着与规模化和成本相关的持续挑战。已有六种FDA批准的AAV疗法上市，更多疗法处于后期临床试验阶段，因此优化上游生产的需求前所未有地迫切。

Enter KyFect™ - AAV. Leveraging the long history of Kyfora by Polysciences in specialty chemical manufacturing, KyFect™ - AAV is designed to synergistically enhance plasmid DNA binding and release at the appropriate stages of the transfection process. Built for flexibility and scale, it enables efficient plasmid delivery, high-yield viral titers, and reproducible performance from early-stage discovery through upstream process development. .

引入 KyFect™ - AAV。凭借 Polysciences 在特种化学制造领域中 Kyfora 的悠久历史，KyFect™ - AAV 旨在协同增强转染过程适当阶段的质粒 DNA 结合与释放。其设计灵活且可扩展，能够实现高效的质粒递送、高产量的病毒滴度，并在从早期发现到上游工艺开发的过程中提供可重复的性能。

'KyFect™ – AAV was developed with our customers' entire product lifecycle in mind,' said Leena Mol Thuruthippallil, PhD, Vice President of Commercial Strategy and Development at Kyfora Bio. 'From early discovery to GMP manufacturing, our reagents empower gene therapy developers to achieve higher titers with fewer resources, accelerating timelines and reducing costs without compromising quality.'.

“KyFect™ – AAV 的开发充分考虑了我们客户整个产品生命周期，” Kyfora Bio 商业战略与发展副总裁 Leena Mol Thuruthippallil 博士表示。“从早期发现到 GMP 生产，我们的试剂助力基因治疗开发者以更少的资源实现更高的滴度，加快进度、降低成本，同时不牺牲质量。”

With its robust scalability and unmatched flexibility, KyFect™ – AAV stands to transform viral vector manufacturing and to help make life-changing gene therapies more accessible than ever before.

凭借其强大的可扩展性和无与伦比的灵活性，KyFect™ – AAV 有望彻底改变病毒载体的生产，并帮助使改变生命的基因疗法变得比以往任何时候都更易获取。

'KyFect™ – AAV represents a significant advancement in upstream AAV manufacturing,' said Andrew Ott, CEO at Kyfora Bio. 'By delivering consistent, high-yield titers while addressing key scalability and cost-efficiency challenges, we are closer to bringing the promise of gene therapy to those who need it.'.

“KyFect™ – AAV 在上游AAV制造方面代表了重大进步，” Kyfora Bio首席执行官Andrew Ott表示。“通过提供稳定且高产量的滴度，同时解决关键的可扩展性和成本效益挑战，我们离将基因治疗的希望带给需要它的人们更近了一步。”

About KyFora Bio

关于KyFora生物

Kyfora Bio delivers high-performance transfection reagents, excipients, and next-gen solutions that empower the development of cutting-edge cell and gene therapies. As a subsidiary of Polysciences—an industry leader with over 60 years of chemical manufacturing expertise—Kyfora leverages scientific innovation to revolutionize the future of advanced therapies, from discovery to delivery..

Kyfora Bio 提供高效转染试剂、辅料和下一代解决方案，助力尖端细胞与基因疗法的开发。作为拥有60多年化学制造经验的行业领导者Polysciences的子公司，Kyfora通过科学创新彻底改变从发现到递送的先进疗法未来。